HPV. Anal high risk human papillomavirus (HPV) DNA test positive
Conditions
Interventions
Intervention 1: Intervention group: All participants in this group will receive capsules containing Lactobacillus, manufactured by Zist-Takhmir Company, administered once daily for a duration of six m
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Women aged 30 to 50 years Not menopausal HR.HPV infection criteria include: Positive HR.HPV test (with a new HPV test within the past 6 months) Diagnosis of low-grade squamous intraepithelial lesion (LSIL) by cytology Willing to use an effective method of contraception during the study period Negative pregnancy test within the past 7 days Normal hematology, renal, and liver function tests
Exclusion criteria
Exclusion criteria: History of myocardial infarction, unstable angina, heart failure, or uncontrolled hypertension (=140.90 mmHg) within the past 6 months Systemic treatment for HR.HPV infection within the past 3 months Acute genital infectionPreviously or currently diagnosed malignant tumor Cytological diagnosis of ASC.H, AGC with potential for malignant transformation, or other high-risk lesionsHistological diagnosis of high-grade squamous intraepithelial lesion (HSIL) Documented psychiatric disorders (schizophrenia, psychosis) or uncontrolled epilepsy Significant medical conditions including immunosuppressive disorders (e.g., HIV, rheumatoid arthritis) or current use of immunomodulatory drugs (e.g., immunosuppressive agents) Autoimmune diseases Use of other dietary supplements with imm unomodulatory effects Presence of hepatic, renal, or hematological disease Chronic illnesses, and use of medications that may affect mood (including antidepressants, anti-psychotics, sedatives), alcohol dependence and/or substance abuse any condition that may impair sexual function (including vaginal stenosis, vaginal dryness, active vaginitis, vaginismus, or vaginal atrophy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV. Timepoint: At the end of month 6 from the start of the study. Method of measurement: HPV Test.;Quality of life, anxiety and depression. Timepoint: Before and after study. Method of measurement: Beck Anxiety Inventory; Beck Depression Inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Shaker ardekani
Tehran University of Medical Sciences
Outcome results
None listed